Inceptive Nucleics co-founder and CEO Jakob Uszkoreit, a co-inventor of the transformer architecture underlying generative models such as ChatGPT, is bringing his artificial intelligence expertise to Alnylam's RNAi platform. The partnership is designed to shift drug discovery away from traditional trial-and-error methods. Inceptive's foundation models learn biological patterns and can adapt to different therapeutic modalities without retraining. In joint exploratory work, the model achieved strong performance within weeks, extracting meaningful insights from relatively small datasets to characterize siRNA molecules, the active ingredient in RNAi therapeutics.

This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.

(END) Dow Jones Newswires

June 03, 2026 17:28 ET (21:28 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.